Potential of Urinary Metabolites for Diagnosing Multiple Sclerosis

被引：15

作者：

Gebregiworgis, Teklab ^{[1
]}

Massilamany, Chandirasegaran ^{[2
]}

Gangaplara, Arunakumar ^{[2
]}

Thulasingam, Sivasubramani ^{[2
]}

Kolli, Venkata ^{[1
]}

Werth, Mark T. ^{[3
]}

Dodds, Eric D. ^{[1
]}

Steffen, David ^{[2
]}

Reddy, Jay ^{[2
]}

Powers, Robert ^{[1
]}

机构：

[1] Univ Nebraska Lincoln, Dept Chem, Lincoln, NE 68588 USA

[2] Univ Nebraska Lincoln, Sch Vet Med & Biomed Sci, Lincoln, NE 68588 USA

[3] Nebraska Wesleyan Univ, Dept Chem, Lincoln, NE 68504 USA

来源：

ACS CHEMICAL BIOLOGY | 2013年 / 8卷 / 04期

基金：

美国国家卫生研究院;

关键词：

EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; FINGOLIMOD FTY720; ORAL FINGOLIMOD; T-CELLS; METABOLOMICS; BIOMARKERS; DISCOVERY; RESPONSES; ACIDURIA; BETA;

D O I：

10.1021/cb300673e

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

A definitive diagnostic test for multiple sclerosis (MS) does not exist; instead physicians use a combination of medical history, magnetic resonance imaging, and cerebrospinal fluid analysis (CSF). Significant effort has been employed to identify biomarkers from CSF to facilitate MS diagnosis; however, none of the proposed biomarkers have been successful to date. Urine is a proven source of metabolite biomarkers and has the potential to be a rapid, noninvasive, inexpensive, and efficient diagnostic tool for various human diseases. Nevertheless, urinary metabolites have not been extensively explored as a source of biomarkers for MS. We demonstrate that urinary metabolites have significant promise for monitoring disease-progression, and response to treatment in MS patients. NMR analysis of urine permitted the identification of metabolites that differentiate experimental autoimmune encephalomyelitis (EAE)-mice (prototypic disease model for MS) from healthy and MS drug-treated EAE mice.

引用

页码：684 / 690

页数：7

共 39 条

[1]

Aktas O., 2010, Hot Top. Neurol. Psychiatry, V9, P29

[2] Fingolimod is a potential novel therapy for multiple sclerosis [J].